In Vivo Cyclophosphamide and IL-2 Treatment Impedes Self-Antigen-Induced Effector CD4 Cell Tolerization: Implications for Adoptive Immunotherapy

Journal of Immunology

Volumn 172, Issue 9, 2004, Pages 5338-5345

  Mihalyo, Marianne A ^a   Doody, Amy D H ^a   McAleer, Jeremy P ^a   Nowak, Elizabeth C ^a   Long, Meixiao ^a   Yang, Yi ^a   Adler, Adam J ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; VACCINE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNITY; CANCER THERAPY; CELL FUNCTION; CONTROLLED STUDY; EFFECTOR CELL; EX VIVO STUDY; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; LYMPHOCYTOPENIA; MOUSE; NONHUMAN; PARENCHYMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 2142828660     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.9.5338     Document Type: Article

References (56)

1. Pardoll, D. 2003. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21:807.
2. Yee, C., S. R. Riddell, and P. D. Greenberg. 1997. Prospects for adoptive T cell therapy. Curr. Opin. Immunol. 9:702.
3. + T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur. J. Immunol. 26:2671.
4. Stavely-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95:1178.
5. + T cell- and IL-2-dependent mechanism. Immunity 11:483.
6. Hu, J., W. Kindsvogel, S. Busby, M. C. Bailey, Y. Shi, and P. D. Greenberg. 1993. An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J. Exp. Med. 177:1681.
7. Morgan, D. J., H. T. Kreuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll, and L. A. Sherman. 1998. Activation of low avidity CTL specific for a self-epitope results in tumor rejection but not autoimmunity. J. Immunol. 160:643.
8. Reilly, R. T., M. B. Gottlieb, A. M. Ercolini, J. P. Machiels. C. E. Kane, F. I. Okoye, W. J. Muller, K. H. Dixon, and E. M. Jaffee. 2000. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 60:3569.
9. Higgins, A. D., M. A. Mihalyo, and A. J. Adler. 2002. Effector CD4 cells are tolerized upon exposure to parenchymal self-antigen. J. Immunol. 169:3622.
10. + T cells undergo peripheral tolerance. Immunity 17:73.
11. Long, M., A. D. Higgins, M. A. Mihalyo, and A. J. Adler. 2003. Effector CD4 cell tolerization is mediated through functional inactivation and involves preferential impairment of TNF-α and IFN-γ expression potentials. Cell. Immunol. 224:114.
12. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99:16168.
13. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850.
14. North, R. J. 1982. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 155:1063.
15. Greenberg, P. D., and M. A. Cheever. 1984. Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells. J. Immunol. 133:3401.
16. Hoover, S. K., S. K. Barrett, T. M. Turk, T. C. Lee, and H. D. Bear. 1990. Cyctophosphamide and abrogation of tumor-induced suppressor T cell activity. Cancer Immunol. Immunother. 31:121.
17. Proietti, E., G. Greco, B. Garrone, S. Baccarini, C. Mauri, M. Venditti, D. Carlei, and F. Belardelli. 1998. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J. Clin. Invest. 101:429.
18. high T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95:2024.
19. Maine, G. N., and J. J. Mule. 2002. Making room for T cells. J. Clin. Invest. 110:157.
20. Dummer, W., A. G. Niethammer, R. Baccala, B. R. Lawson, N. Wagner, R. A. Reisfeld, and A. N. Theofilopoulos. 2002. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 110:185.
21. Hu, H. M., C. H. Poehlein, W. J. Urba, and B. A. Fox. 2002. Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res. 62:3914.
22. + T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen presenting cells. J. Exp. Med. 187:1555.
23. Sotomayor, E. M., I. Borrello, F. M. Rattis, A. G. Cuenca, J. Abrams, K. Staveley-O'Carroll, and H. I. Levitsky. 2001. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 98:1070.
24. + T cell tolerance induction versus priming is independent of the rate and number of cell divisions. J. Immunol. 164:649.
25. + single positive cells with a class II major histocompatibility complex-restricted receptor. J. Exp. Med. 180:25.
26. Higgins, A. D., M. A. Mihalyo, P. W. McGary, and A. J. Adler. 2002. CD4 cell priming and tolerization are differentially programmed by APCs upon initial engagement. J. Immunol. 168:5573.
27. Reinhardt, R. L., A. Khoruts, R. Merica, T. Zell, and M. K. Jenkins, 2001. Visualizing the generation of memory CD4 T cells in the whole body. Nature 410:101.
28. + T cells or CTL immunotherapy of tumors expressing the antigen. J. Immunol. 166:2863.
29. Marrack, P., and J. Kappler. 1990. The staphylococcal enterotoxins and their relatives. Science 248:705.
30. Beutler, B., and A. Cerami. 1987. Cachectin: more than a tumor necrosis factor. N. Engl. J. Med. 316:379.
31. Alegre, M., P. Vandenabeele, V. Flamand, M. Moser, O. Leo, D. Abramowicz, J. Urbain, W. Fiers, and M. Goldman. 1990, Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor. Eur. J. Immunol. 20:707.
32. Dummer, W., B. Ernst, E. LeRoy, D. Lee, and C. Surh. 2001. Autologous regulation of naive T cell homeostasis within the T cell compartment. J. Immunol. 166:2460.
33. + T cells in the antitumor immune response. J. Exp. Med. 188:2357.
34. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN γ receptor expression by nonhematopoietic cells. Immunity 12:677.
35. Ikeda, H., L. J. Old, and R. D. Schreiber. 2002. The roles of IFN γ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13:95.
36. Poehlein, C. H., H. M. Hu, J. Yamada, I. Assmann, W. G. Alvord, W. J. Urba, and B. A. Fox. 2003. TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-γ double knockout effector T cells. J. Immunol. 170:2004.
37. Winter, H., H. M. Hu, K. McClain, W. J. Urba, and B. A. Fox. 2001. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-γ in vaccine-induced antitumor immunity versus adoptive immunotherapy. J. Immunol. 166:7370.
38. Matsui, K., L. A. O'Mara, and P. M. Allen. 2003. Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy. Int. Immunol. 15:797.
39. Yee, C., J. A. Thompson, P. Roche, D. R. Byrd, P. P. Lee, M. Piepkom, K. Kenyon, M. M. Davis, S. R. Riddell, and P. D. Greenberg. 2000. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med. 192:1637.
40. Wucherpfennig, K. W., and J. L. Strominger. 1995. Molecular mimicry in T cell-mediated autoimmumty: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80:695.
41. Gross, D. M., T. Forsthuber, M. Tary-Lehmann, C. Etling, K. Ito, Z. A. Nagy, J. A. Field, A. C. Steere, and B. T. Huber. 1998. Identification of LFA-I as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281:703.
42. Bachmaier, K., N. Neu, L. M. de la Maza, S. Pal, A. Hessel, and J. M. Penninger. 1999. Chlamydia infections and heart disease linked through antigenic mimicry. Science 283:1335.
43. Ohteki, T., A. Hessel, M. F. Bachmann, A. Zakarian, E. Sebzda, M. S. Tsao, K. McKall-Faienza, B. Odermatt, and P. S. Ohashi. 1999. Identification of a cross-reactive self ligand in virus-mediated autoimmunity. Eur. J. Immunol. 29:2886.
44. Panoutsakopoulou, V., M. E. Sanchirico, K. M. Huster, M. Jansson, F. Granucci, D. J. Shim, K. W. Wucherpfennig, and H. Cantor. 2001. Analysis of the relationship between viral infection and autoimmune disease. Immunity 15:137.
45. Lang, H. L., H. Jacobsen, S. Ikemizu, C. Andersson, K. Harlos, L. Madsen, P. Hjorth, L. Sondergaard, A. Svejgaard, K. Wucherpfennig, et al. 2002. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol. 3:940.
46. Ohashi, P. S., S. Oehen, K. Buerki, H. Pircher, C. T. Ohashi, B. Odermatt, B. Malissen, R. M. Zinkemagel, and H. Hengartner. 1991. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65:305.
47. Oldstone, M. B., M. Nerenberg, P. Southern, J. Price, and H. Lewicki. 1991. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 65:319.
48. Kurts, C., W. R. Heath, F. R. Carbone, J. Allison, J. F. Miller, and H. Kosaka. 1996. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 184:923.
49. Morgan, D. J., C. Kurts, H. T. Kreuwel, K. L. Holst, W. R. Heath, and L. A. Sherman. 1999. Ontogeny of T cell tolerance to peripherally expressed antigens. Proc. Natl. Acad. Sci. USA 96:3854.
50. + T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4:1009.
51. Berd, D., H. C. Maguire, Jr., and M. J. Mastrangelo. 1986. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 46:2572.
52. + T cells. J. Surg. Oncol. 67:221.
53. Machiels, J. P., R. T. Reilly, L. A. Emens, A. M. Ercolini, R. Y. Lei, D. Weintraub, F. I. Okoye, and E. M. Jaffee. 2001. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61:3689.
54. Blattman, J. N., J. M. Grayson, E. J. Wherry, S. M. Kaech, K. A. Smith, and R. Ahmed. 2003. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9:540.
55. D'Souza, W. N., and L. Lefrancois. 2003. IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. J. Immunol. 171:5727.
56. + T cells. J. Exp. Med. 198:1107.